Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Seminars in Oncology
|
January 5, 2002
Cancer vaccines targeting the HER2/neu oncogenic protein
M L Disis, K Schiffman
Clinical Lung Cancer
|
January 21, 2004
HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers
K Schiffman, M L Disis
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 27, 2001
Issues on clinical applications of cancer vaccines
M L Disis, K Schiffman
Clinical Breast Cancer
|
March 20, 2002
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine
K L Knutson, M L Disis
Critical Reviews in Immunology
|
January 7, 1998
HER-2/neu oncogenic protein: issues in vaccine development
M L Disis, M A Cheever
Archivum Immunologiae Et Therapiae Experimentalis
|
May 12, 2000
Tumor vaccines for the management of prostate cancer
D G McNeel, M L Disis
Current Opinion in Immunology
|
October 1, 1996
Oncogenic proteins as tumor antigens
M L Disis, M A Cheever
Advances in Cancer Research
|
January 1, 1997
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer
M L Disis, M A Cheever
Clinical and Experimental Immunology
|
January 24, 2004
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion
K L Knutson, M L Disis
Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|
December 27, 2005
Augmenting T helper cell immunity in cancer
K L Knutson, M L Disis
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Seminars in Oncology
|
January 5, 2002
Cancer vaccines targeting the HER2/neu oncogenic protein
M L Disis, K Schiffman
Clinical Lung Cancer
|
January 21, 2004
HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers
K Schiffman, M L Disis
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 27, 2001
Issues on clinical applications of cancer vaccines
M L Disis, K Schiffman
Clinical Breast Cancer
|
March 20, 2002
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine
K L Knutson, M L Disis
Critical Reviews in Immunology
|
January 7, 1998
HER-2/neu oncogenic protein: issues in vaccine development
M L Disis, M A Cheever
Archivum Immunologiae Et Therapiae Experimentalis
|
May 12, 2000
Tumor vaccines for the management of prostate cancer
D G McNeel, M L Disis
Current Opinion in Immunology
|
October 1, 1996
Oncogenic proteins as tumor antigens
M L Disis, M A Cheever
Advances in Cancer Research
|
January 1, 1997
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer
M L Disis, M A Cheever
Clinical and Experimental Immunology
|
January 24, 2004
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion
K L Knutson, M L Disis
Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|
December 27, 2005
Augmenting T helper cell immunity in cancer
K L Knutson, M L Disis
Page
of 5